Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies by Laux, I et al.
Epidermal growth factor receptor dimerization status determines
skin toxicity to HER-kinase targeted therapies
I Laux
1,3, A Jain
1,3, S Singh
2 and DB Agus*,1
1Louis Warschaw Prostate Cancer Center, Cedar-Sinai Medical Center, 8631 West Third Street, Suite 1001E, Los Angeles, CA 90048, USA;
2Monogram Biosciences, Inc., 345 Oyster Point Blvd., South San Francisco, CA 94080-1913, USA
Skin toxicity, a common drug-related adverse event observed in cancer patients treated with epidermal growth factor receptor
(EGFR)-directed therapies is rarely seen with therapies targeting HER2. This study reports the significance of the EGFR and HER2
dimerization status in skin with regard to these dermatologic side effects. We demonstrate the differential effect of HER-directed
therapies on the ligand driven activation status of EGFR, HER2 and MAPK in normal human epidermal keratinocytes. EGFR-directed
therapies, such as gefitinib and cetuximab, inhibited ligand-induced activation of EGFR and MAPK in human keratinocytes.
Pertuzumab, an antibody interfering with functional HER2 heterodimerization, failed to block ligand-induced HER signaling in primary
keratinocytes. Using a novel proximity-based dimerization assay (eTagt) we show that EGFR homodimers are the predominant HER
dimer pair in normal primary kertinocytes and in normal skin tissue from 16 patients with solid malignancies. The presence of [p]EGFR
and [p]MAPK, but the absence of [p]HER2, demonstrates productive signaling via EGFR but not HER2 in human skin. These data
illustrate the importance of the EGFR dimerization partner in human skin and suggests that inhibition of EGFR homodimer signaling
rather than EGFR/HER2 heterodimer signaling maybe the key molecular event determining dermatologic toxicity discrepancies
observed between EGFR-targeted versus HER2-targeted therapies.
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Members of the human epidermal receptor (HER/ErbB) family, in
particular epidermal growth factor receptor (EGFR/HER1/ErbB1)
and HER2/neu/ErbB2 play key roles in the tumorigenic process
of epithelial cancers and have been attractive candidates for the
development of target-based treatment strategies. Considerable
progress in drug development targeting EGFR and/or HER2
has been made providing promising treatment options in a subset
of solid malignancies (Mendelsohn and Baselga, 2000; Arteaga,
2003; Rowinsky, 2003).
Skin rash and diarrhea are the most common side effects in
patients treated with EGFR-directed therapies. Cutaneous toxi-
cities, commonly defined as rash, acne, pruritus and dry skin, have
been reported as one of the predominant side effects in cancer
patients treated with small-molecule tyrosine kinase inhibitors
(TKI) of EGFR (gefitinib, erlotinib), dual EGFR/HER2 (lapatinib)
inhibitors, pan-HER (CI-1033) inhibitors and anti-EGFR anti-
bodies (cetuximab, ABX-EGF and EMD72000) (Busam et al, 2001;
Hidalgo et al, 2001; Shin et al, 2001; Fukuoka et al, 2003; Kris et al,
2003; Burris, 2004; Rowinsky et al, 2004; Vanhoefer et al, 2004).
Interestingly, the characteristic cutaneous side effects observed
with EGFR-directed therapies have not been reported for therapies
targeting HER2, such as trastuzumab and pertuzumab (2C4,
Omnitargt). Pertuzumab is a HER2-specific humanized mono-
clonal antibody, which inhibits ligand-mediated intracellular
signaling by blocking functional HER2 heterodimerization
(Agus et al, 2002; Mendoza et al, 2002). Pertuzumab has a
favorable toxicity profile and demonstrated clinical activity in a
Phase I clinical trial in patients with advanced solid cancers (Agus
et al, 2005b). Skin rash of grade 2 and greater (NCI-CTC) is dose
dependent and occurs in 20–50% of patients treated with EGFR-
directed therapies such as gefitinib (Fukuoka et al, 2003), erlotinib
(Soulieres et al, 2004) and cetuximab (Saltz et al, 2004). However,
only about 1% of the patients in phase I and II studies with
pertuzumab developed skin rash greater than grade 1 which did
not demonstrate the rash characteristics typical for EGFR inhibitor
therapy (Agus et al, 2005a,b); (S Kelsey, Genentech, personal
communication).
Skin has been suggested as a surrogate tissue for pharmaco-
dynamic endpoint evaluation for EGFR-directed therapies because
it is easy assessable, expresses EGFR and frequently develops
toxicity following these therapies (Baselga, 2003). Several clinical
studies have shown a positive correlation of the incidence of skin
rash and tumour response or survival (Baselga, 2003; Clark et al,
2003; Cohen et al, 2003; Perez-Soler, 2003; Saltz et al, 2003; Perez-
Soler et al, 2004; Soulieres et al, 2004). However, other studies have
failed to observe this correlation (Tan et al, 2004). Although skin
rash may be a pharmacodynamic marker of drug action (Albanell
et al, 2002; Malik et al, 2003), its predictive value and potential as a
surrogate marker for response to EGFR-targeted agents depends
on the correlation of HER-kinase signaling in paired skin and
tumour tissue which requires further investigation.
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question and analyzes the molecular mechanism(s) potentially
responsible for skin rash observed in patients treated with HER-
kinase directed therapies.
MATERIALS AND METHODS
Material
RPMI 1640 and Keratinocyte Growth Medium (KGM) were
obtained from ATCC and Cambrex (Walkersville, MD, USA),
respectively. Antibodies were purchased as follows: EGFR (#2232),
HER2 (#2242), pEGFR (#2236), pHER2 (#2249) and pMAPK
(#9101) from Cell Signaling Technology (Beverly, MA, USA),
HER3 (2F12) from Neomarkers (Fremont, CA, USA), b-actin from
Sigma (St Louis, MO, USA). Secondary horseradish peroxidase-
conjugated anti-rabbit and anti-mouse antibodies were obtained
from Amersham Biosciences (Piscataway, NJ, USA). EGF was
purchased from Invitrogen (Carlsbad, CA, USA), TGFa from
Calbiochem (Fremont, CA, USA) and heregulin (HRG) from R&D,
Minneapolis, MN, USA).
Cell culture
Adult normal human epidermal keratinocytes (NHEK) were
obtained from Cambrex (Walkersville, MD, USA) and maintained
in KGM medium supplemented with growth factors, cytokines and
supplements according to manufacturer’s instructions. 22Rv1 cells
(ATCC) or MCF7 cells (ATCC) were cultured in RPMI 1640 or
DMEM/F12 containing 10% FBS, 2mML -glutamine and penicillin/
streptomycin (100Uml
 1), respectively.
Cell stimulation and lysis
NHEK were starved overnight in basal KGM medium without
supplements and 22Rv1 cells were serum-starved in RPMI 1640
without phenol red supplemented with 0.02% BSA before
they were treated with increasing concentrations of gefitinib
(AstraZeneca, Alderley Park, Cheshire, UK) for 2h at 371C. Ligand
stimulation was carried out using 4nM EGF, 5nM TGFa or 100nM
HRG for 10min at 371C before cells were lysed in RIPA lysis buffer
(50mM Tris-HCl, 1% NP-40, 0.1% SDS, 0.25% sodium deoxycho-
late, 150mM NaCl, 1mM EDTA). Protein quantitations were
performed using a BCA protein quantitation kit from Pierce
(Rockford, IL, USA).
Immunoblotting and immunoprecipitation
For immunoblotting, cell lysates were heated to 1001C for 5min
in presence of Laemmli sample buffer. Equivalent amounts of
protein lysates were subjected to SDS-polyacrylamide gel electro-
phoresis, transferred to PDVF membranes and immuno-
probed with the appropriate antibodies. Blots were analyzed by
chemiluminescence using HRP-conjugated secondary antibodies
and ECL detection reagent (Amersham Pharmacia Biotech,
Piscataway, NJ, USA).
For immunoprecipitations, cell lysates containing equivalent
amounts of protein were incubated overnight at 41C with 2mgo f
the appropriate antibodies. After adding 20ml of 50% slurry of
protein-A Sepharose beads, cell lysates were incubated for another
2h at 41C. The immunoprecipitates were pelleted by centrifuga-
tion (3000r.p.m., 41C) and washed three times with RIPA lysis
buffer to remove nonspecific proteins. The captured immuno-
complexes were eluted by boiling the beads in a 2  SDS sample
buffer for 5min. The samples were then immunoblotted as
described above.
RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted from cells lines using Trizol reagent
(GIBCO/BRL Life Technologies, MD, USA). DNase I (Ambion, CA,
USA) was used to rid the samples of genomic DNA and total
RNA yield was quantified spectrophotometrically. The RT-PCR
was performed by using TAQman One-Step RT-PCR Master Mix
Reagents Kit (Applied Biosystems, Foster City, CA, USA). PCR
cycling conditions were as follows: 30min at 481C for RT step;
10min at 951C for AmpliTaq Gold Activation; and 40 cycles for
denaturation (951C, 15s), and annealing/elongation (601C for
1min) steps. PCR reactions for each template were run in triplicate
using 1mg of total RNA per sample. The sequences of the primer/
probe sets for the HER-kinase axis were described previously
(Agus et al, 2002). Standard curves were constructed for each gene-
specific primer pair using 10–1000ng of total RNA prepared from
CWR22R xenografts. b-Actin was used as a normalization control
using the following primer/probe set: (F) 50-GCGCGGCTACAG
CTTCA-30,( R )5 0-TCTCCTTAATGTCACGCACGAT-30, (P) 50-FAM-
CACCACGGCCGAGCGGGA-TAMRA-30. All of the experiments
were optimized such that the threshold cycle (CT) from triplicate
reactions did not span more than one cycle number. The
comparative CT method (PE Applied Biosystems, Foster City,
CA, USA) was used to determine relative quantification of gene
expression for each gene compared with the b-actin control.
Average CT values from triplicate PCR reactions for the genes of
interest were normalized to average CT values for b-actin from the
same RNA/cDNA preparation.
Patient skin samples
Sixteen formalin-fixed paraffin-embedded (FFPE) skin tissue
samples from patients with solid tumours who had previously
undergone surgical procedures at Cedars-Sinai Medical Center
(CSMC) were analyzed. The skin tissue was collected after
informed consent was obtained from each patient. All human
investigations were performed after approval by an institutional
review board.
Proximity-based eTagt assays
eTagt assays are multiplexed proximity-based assays that evaluate
protein expression, dimerization and phosphorylation simulta-
neously via multi-label binding of specific antibodies to non-
overlapping epitopes on the same protein and/or interacting
protein partners (Miller, 2002; Chan-Hui et al, 2004). HER-
receptor phosphorylation was evaluated with antiphosphotyrosine
antibodies and ERK phosphorylation was assessed with an
antiphospho ERK1/2 antibody. The multiple antibody–analyte
binding events occur in the solution phase of the lysates during
incubation for 1h at RT to overnight at 41C. Typically, each
antibody is conjugated with a unique fluorescent eTagt moiety
via a cleavable linker. Each eTagt is distinguishable from each
other upon analysis by capillary electrophoresis (CE). One specific
antibody is coupled to a ‘molecular scissor’, which upon
illumination by green light will emit singlet oxygen. eTagt
reporters that locate within a couple of hundred nanometers from
the ‘molecular scissor’ are released via photo cleavage of the linker
by singlet oxygen and then collected for CE analysis following a
buffer exchange step to remove excess salt. The identification of
each eTagt reporter is determined with eTagt Informer software
and the quantification is based on the CE peak area normalized to
an internal CE standard marker.
Cell lysates were prepared by adding 500ml of ice-cold ACLARA
lysis buffer per 10cm dish containing phosphatase and protease
inhibitors. Crude extracts were microcentrifuged at 14000r.p.m.
for 10min at 41C to remove insoluble materials. The total protein
concentration in each lysate was determined by BCA assay (Pierce,
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buffer in a 7-point titration curve ranging from 100 to 1.6mg total-
protein equivalents per assay. The analysis at each titration point
was performed in triplicates. Background for the eTagt reporter
readout was determined by omitting the cell lysates in the assay
and later subtracting it from each sample. The eTagt readouts in
relative fluorescence units (RFU) correspond to 20mg total
protein-equivalents of lysates that reside in the linear portion on
the titration curves throughout all samples used for reporting.
FFPE skin sections on glass slides were analyzed with two
multiplexed eTagt assays. One assay was used to analyze EGFR
homodimerization and EGFR phosphorylation on tyrosine residues.
A second assay was used to determine HER2 phosphorylation.
Receptor phosphorylation was measured using the proximity-based
release of eTagt reporter from conjugated antiphospho-tyrosine
on the same molecules bound by scissor-coupled anti-EGFR or
anti-HER2. To measure EGFR homodimerization, a single mono-
clonal antibody was separately coupled with either the ‘molecular
scissor’ or another eTagt reporter. Since the monoclonal anti-
body binds to a single epitope, the scissor and reporter will
be in proximity only when EGFR forms a homodimer with itself.
Approximately half of such homodimerization events will
lead to the proximity-based eTagt release when the scissor-
anti-EGFR and eTagt -anti-EGFR are mixed at 1:1 ratio in the
assay. To normalize EGFR homodimerization, EGFR or HER2
phosphorylation readouts for cellular content in each tissue
section and the variation in section size, tubulin was used as an
internal control. Tubulin was quantified in the same multiplexed
assay by including two nonoverlapping tubulin-specific antibodies,
one conjugated with a unique eTagt reporter and the other
coupled with the ‘molecular scissor’.
EGFR, HER2 and HER3 expression data and phospho-EGFR and
phospho-ERK data are presented as the average relative fluores-
cence units (RFU) of a triplicate analysis for each sample including
the standard deviation. EGFR homodimerization and EGFR/HER2
heterodimerization data are presented as the ratio of homodime-
rized EGFR to total EGFR or heterodimerized EGFR to total HER2,
respectively. These ratios are the average of a triplicate analysis for
each sample. Standard deviations were calculated for each ratio.
RESULTS
EGFR is the major HER/ErbB receptor in primary human
keratinocytes
To characterize the abundance of the HER-kinase receptors in
primary normal human epidermal keratinocytes (NHEK), protein
expression levels for EGFR, HER2 and HER3 were assessed
and compared to cancer cell lines of various origins with known
HER-kinase receptor expression patterns (Figure 1A). EGFR was
found to be the major HER-kinase receptor expressed in human
keratinocytes as previously reported by other groups (Rodeck
et al, 1997; Jost et al, 2000). HER2 was also expressed to significant
levels while HER3 could not be detected. These results were
confirmed by real-time quantitative RT-PCR analysis (Figure 1B).
The HER-kinase pathway is functional in primary human
keratinocytes and can be inhibited by gefitinib or
cetuximab but not with pertuzumab
We examined the dose escalating effect of gefitinib treatment on
EGFR and MAPK phosphorylation after ligand stimulation since
these phosphorylated proteins are functional surrogates for an
activated HER signaling pathway (Albanell et al, 2001). EGF was
able to stimulate EGFR and MAPK phosphorylation in NHEK that
could be inhibited by gefitinib in a dose-dependent manner
(Figure 2A). A lower concentration of gefitinib blocked ligand
stimulated EGFR phosphorylation in human keratinocytes,
whereas significant inhibition of downstream signaling, that is,
MAPK phosphorylation, was achieved only at higher doses of
gefitinib. The inhibitory concentrations of gefitinib in NHEK were
similar to those observed for blocking pEGFR and pMAPK in
22Rv1 cells (Figure 2B), an androgen-independent prostate cancer
cell line (Sramkoski et al, 1999). This confirms previously reported
observations of differential inhibition of EGFR and MAPK
phosphorylation in glioma cell lines (Li et al, 2003) and shows
the effectiveness of gefitinib against EGFR signaling in human
keratinocytes. To compare the effect of gefitinib with an anti-EGFR
antibody, NHEK were treated with cetuximab, an anti-EGFR
humanized chimeric mouse monoclonal antibody, which competi-
tively inhibits receptor binding of EGF and other EGFR ligands
(Mendelsohn, 2001). Figure 2C demonstrates that cetuximab was
able to completely block [p]EGFR and [p]MAPK in primary
human keratinocytes. Taken together, these results demonstrate
that in primary human keratinocytes, EGF-dependent HER-
receptor signaling can be specifically and completely blocked by
EGFR-targeted therapies.
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Figure 1 HER-kinase receptor expression in NHEK and various cancer
cell lines. (A) Immunoblot analysis of cell lysates from NHEK and various
cancer cell lines. Cells were lysed and equal amounts of total protein were
subjected to SDS-PAGE and transferred to a PDVF-membrane. The blot was
probed with specific antibodies to EGFR, HER2 and HER3 and reprobed for
b-actin to account for loading differences. (B) Real time quantitative RT-PCR
analysis of EGFR, HER2 and HER3 mRNA expression in MCF-7 cells (light
gray bars), 22Rv1 cells (dark gray bars) and NHEK (black bars). The absolute
receptor mRNA expression levels were normalized to b-actin mRNA
expression. The data for each receptor is presented as relative receptor
expression of the evaluated cell lines to each other.
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sUnlike gefitinib and cetuximab, pertuzumab, which is a HER2-
specific antibody that interferes with its heterodimerization with
other receptor members, was unable to block EGF stimulated
EGFR or MAPK phosphorylations in NHEK (Figure 3A). EGF was
unable to induce HER2 phosphorylation in NHEK (Figure 3A)
suggesting against the presence of a functional HER2 receptor in
primary human keratinocytes even though HER2 protein is
expressed. A parallel analysis of 22Rv1 cells demonstrated an
activation of EGFR as well as HER2 in response to EGF, which
could be inhibited by pertuzumab (Figure 3B). This suggests the
formation of EGFR/HER2 heterodimers after EGF stimulation in
22Rv1 cells, but not in NHEK, since ligand-dependent activation of
HER-kinase receptors is known to occur through the formation of
receptor dimers (Yarden and Sliwkowski, 2001). These results are
in accordance with the observation that pertuzumab inhibits
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gefitinib −
− + − + −
100 nM 1000 nM
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− + − + −
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Figure 2 Effect of gefitinib and cetuximab on primary human
keratinocytes. Representative immunoblots of lysates from NHEK (A, C)
and 22Rv1 cells (B) are shown. (A) NHEK and (B) 22Rv1 cells were
serum-starved for 24h and treated with increasing levels of gefitinib 2h
before stimulation with 4nM EGF for 10min at 371C. (C) NHEK were
serum-starved for 24 hrs in the absence or presence of 5mgml
 1
cetuximab before stimulation with 4nM EGF for 10min at 371C. Following
stimulation cells were lysed in RIPA buffer and equal amounts of total
protein were subjected to SDS-PAGE and transferred to PDVF-
membranes. Blots were analyzed with specific antibodies to pEGFR, EGFR,
pMAPK as indicated and reprobed for b-actin to account for loading
differences.
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Figure 3 Effect of 2C4 on primary human keratinocytes. Representative
immunoblots of lysates from NHEK (A) and 22Rv1 (B) cells are shown.
Cells were starved in serum-free media for 24h and treated with or
without 100nM pertuzumab 2h before stimulation with 4nM EGF or 5nM
TGFa for 10min at 371C. Cells were lysed and equal amounts of protein
lysate were subjected to SDS-PAGE, transferred to PDVF-membranes and
analyzed by using specific antibodies to EGFR, pEGFR, HER2 and pHER2,
pMAPK. Blots were reprobed for b-actin to account for loading differences.
Figure 4 EGFR homodimers are the preferred dimerization form in normal human skin. NHEK and 22Rv1 cell lysates as well as FFPE human tissue
samples and FFPE cancer cell lines were analyzed for total HER-receptor expression, phosphorylation, dimerization and ERK activation using eTagt assays.
(A) Comparison of EGFR homodimerization and EGFR/HER2 heterodimerization in NHEK and 22R1 cells. Data are presented as the ratio of dimerized
EGFR to total EGFR and dimerized EGFR to total HER2 in each sample, respectively. (B) HER-kinase receptor expression in 16 normal human skin specimen
(1–16) in comparison to MDA-MB-468 (17) and MCF-7 cells (18). Each bar represents the average relative fluorescence unit (RFU) of a triplicate analysis
for each sample. (C) EGFR homodimerization in normal human skin samples (1–16) and MDA-MB-468 cells. EGFR homodimers are presented as the ratio
of dimerized EGFR to total EGFR in each sample. Each bar represents the average value for a triplicate analysis for each sample. (D) EGFR phosphorylation
and ERK activation in normal human skin specimen (1–16), MDA-MB-468 cells and MCF-7 cells. Data are presented as relative fluorescence units (RFU) for
phosphorylated EGFR and phosphorylated ERK, respectively. Each bar represents an average value of a triplicate analysis for each sample.
EGFR dimerization status and skin toxicity
I Laux et al
88
British Journal of Cancer (2006) 94(1), 85–92 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sR
a
t
i
o
 
o
f
 
d
i
m
e
r
i
z
e
d
 
E
G
F
R
t
o
 
t
o
t
a
l
 
E
G
F
R
0
0.02
0.04
0.06
0.08
0.1
22Rv1 NHEK
EGFR/EGFR (eTagTM)
R
a
t
i
o
 
o
f
 
d
i
m
e
r
i
z
e
d
 
E
G
F
R
t
o
 
t
o
t
a
l
 
H
E
R
2
0
0.02
0.04
0.06
0.08
0.1
0.12
22Rv1 NHEK
EGFR/HER2 (eTagTM) 
P
e
a
k
 
a
r
e
a
 
(
R
F
U
)
Normal human skin
Normal human skin
Normal human skin
MDA-MB-468
MCF-7
56000
12000
8000
4000
0
EGFR HER2 HER3
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6
R
a
t
i
o
 
o
f
 
h
o
m
o
d
i
m
e
r
i
z
e
d
 
E
G
F
R
t
o
 
t
o
t
a
l
 
E
G
F
R
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 MDA-
MB-
468
EGFR homodimerization (eTagTM)
0
2000
4000
6000
8000
10000
12000
[p]EGFR (eTagTM)
P
e
a
k
 
a
r
e
a
 
(
R
F
U
)
[p]ERK (eTagTM)
P
e
a
k
 
a
r
e
a
 
(
R
F
U
)
0.0
50.0
100.0
150.0
200.0
250.0
300.0
MCF-7
40nM
HRG
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 MDA-
MB-
468
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
A
B
C
D
EGFR dimerization status and skin toxicity
I Laux et al
89
British Journal of Cancer (2006) 94(1), 85–92 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sHER2-containing heterodimers (Agus et al, 2002; Mendoza et al,
2002) and further implies that NHEK lack the formation of such
heterodimers in response to EGF.
HER2 does not interact with EGFR in primary human
keratinocytes
To more specifically interrogate the HER-receptor dimerization
status in primary human keratinocytes, we determined the
presence of HER-kinase dimers in NHEK and 22Rv1 cells using
coimmunoprecipitations and the eTagt System. eTagt Techno-
logy developed by ACLARA BioSciences is a multiplexed, solution
phase analysis of proteins and nucleic acids. The multiplexed
analysis is based on a set of electrophoresis-tag reporters (eTag
reporters) – low molecular weight, fluorescent molecules with
a unique and defined mobility in capillary electrophoresis (CE).
The protein analysis is an antibody-based proximity assay that
quantitatively measures protein–protein interactions (Chan-Hui
et al, 2004; Salimi-Moosavi et al, 2004). eTag reporters are
covalently linked to antibodies that specifically recognize the
target protein. When bound to its target the eTag reporter is
specifically cleaved and analyzed by capillary electrophoresis. The
amount of free eTag reporter generated in the assay is propor-
tional to the quantity of target protein (Miller, 2002). The
eTagt System can detect and quantify as few as several hundred
receptors per cell and exceeds the precision and accuracy
of Western blotting. More importantly, the eTagt System
allows for the evaluation of homodimer presence which typically
cannot be interrogated with traditional coimmunoprecipita-
tion assays.
EGFR coimmunoprecipitation experiments performed after
EGF stimulation failed to demonstrate an EGFR/HER2 interaction
in NHEK (data not shown). The lack of EGF-induced HER2
phosphorylation further argues against the presence of such
heteromers. However, in 22Rv1 cells, EGF was able to induce HER2
phosphorylation that could be specifically blocked by pertuzumab
(Figure 3B) suggesting the presence of EGFR/HER2 heterodimers.
Probably due to assay detection limits we were unable to
demonstrate this interaction in 22Rv1 cells using a coimmuno-
precipitation assay.
Interestingly, in a parallel set of samples from 22Rv1 cells EGFR/
HER2 heterodimers could be unequivocally detected using the
eTagt-based assay (Figure 4A). This demonstrated the presence of
EGFR/HER2 heterodimers after EGF stimulation as well as the
sensitivity of this assay. Further, appreciable levels of EGFR
homodimers were also detected after EGF stimulation in these
cells. Using the eTagt – assay after EGF induction in NHEK
led to the detection of only EGFR homodimers (Figure 4A). This
explains the lack of EGF-induced HER2 phosphorylation in
these cells. The analysis demonstrated a preference for EGFR
homodimerization and the absence of EGFR/HER2 hetero-
dimerization in keratinocytes.
EGFR homodimers are the predominant dimerization form
in human skin
The eTagt System allows the analysis of protein-protein interac-
tions in FFPE clinical samples (Dua et al, 2004). Utilizing this
assay, we studied the expression and dimerization status of HER-
kinase receptors in 16 paraffin-embedded tissue sections of normal
human skin obtained from patients with solid tumours. Figure 4B
represents the expression levels of EGFR, HER2 and HER3 in these
samples with MDA-MB-468 and MCF-7 cells as positive controls.
EGFR, HER2 and HER3 were expressed in all 16 skin samples.
The relative expression levels of various receptors in a given tissue
section, represented by relative fluorescence units (RFU), cannot
be directly compared to each other due to potential affinity and
avidity differences between EGFR, HER2 and HER3 antibodies
attached to distinct eTag reporters.
EGFR homodimers were detected in all 16 skin samples
(Figure 4C), whereas EGFR/HER2 or HER2/HER3 heterodimers
could not be found (data not shown). HER2 heterodimers are
either absent in human skin or exist below the detection limit of
this sensitive assay. All skin specimens also demonstrated EGFR
and MAPK phosphorylation (Figure 4D) indicating a functional
signaling pathway as a consequence of EGFR homodimerization.
HER2 phosphorylation was undetectable in all skin specimens
(data not shown). The EGFR overexpressing breast cancer cell line
MDA-MB-468 forms EGFR homodimers in response to ligand
stimulation. Similarly abundant levels of EGFR homodimers were
measured in all skin samples.
DISCUSSION
Our study provides a molecular rationale for the skin rash
commonly observed with EGFR-targeted therapies (such as
gefitinib and cetuximab) but not with therapies that target the
HER2 receptor (such as pertuzumab and Herceptin). Although the
reason for this discrepancy is unknown, the occurrence of skin
rash has been of particular clinical relevance since several studies
have correlated it with antitumour activity (Cohen et al, 2003; Saltz
et al, 2003; Perez-Soler et al, 2004).
Using a sensitive and quantitative eTagt dimerization assay we
demonstrate that EGFR homodimers are the predominant isoform
in human keratinocytes, while little or no HER2 heterodimers are
found. These results are in disagreement with a previous study
(Marques et al, 1999) that reported the presence of EGFR/HER2,
EGFR/HER3 and HER2/HER3 heterodimers in the human
keratinocyte cell line, HaCaT. However, their technique of choice,
coimmunoprecipitation assay, is unsuited to detect homodimers.
Another study has reported the absence of EGFR/HER2 hetero-
dimers in mouse keratinocytes using coimmunoprecipitation
assays (Xian et al, 1997). Perhaps the reason for such conflicting
results has been the absence of a sensitive and quantitative assay to
unambiguously measure receptor dimers in vivo.
The HER signaling network functions via productive signaling,
that can only occur after the formation of receptor dimers. Our
study demonstrates the absence of a functional target for a HER2-
directed therapy, such as pertuzumab, in human skin due to the
lack of detectable levels of HER2 heterodimers in human
keratinocytes. Therefore, the absence of skin rash with HER2-
directed therapies is not surprising. The functional consequences
of EGFR homodimers and the lack of EGFR/HER2 heterodimers in
primary human keratinocytes were demonstrated by two observa-
tions. First, gefitinib and cetuximab directly interfered with EGFR
signaling by blocking EGFR and MAPK phosphorylation while
pertuzumab did not. Second, HER2, despite considerable expres-
sion levels in keratinocytes and normal skin biopsies, did not
engage into productive heterodimerization complexes as shown by
the lack of HER2 phosphorylation, coimmunoprecipitation and
eTagt dimerization assays. Skin rash occurs when EGFR signaling
is blocked with either antibodies or small molecule inhibitors.
The antibody pertuzumab might not cause skin rash since HER2
does not seem to form any detectable functional HER2 hetero-
dimers in human skin.
There are several speculations as to why HER2 fails to engage
into productive dimerization complexes in human skin even
though it has been suggested as a preferred heterodimerization
partner (Tzahar et al, 1996; Graus-Porta et al, 1997; Hendriks et al,
2003). First, physical separation of EGFR and HER2 within the skin
cells might be responsible for preventing their association (Stoll
et al, 2001). EGFR is primarily expressed in the basal layer of the
keratinocytes while HER2 and HER3 are expressed in the upper
spinous layers (Piepkorn et al, 2003). A second possibility could be
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a key role during keratinocyte proliferation while HER2 is more
important during the differentiation process (De Potter et al,
2001). Therefore, it is possible that EGFR and HER2 are not
activated enough at the same time to cofunction in HER signaling.
Third, studies that have challenged the concept of HER2 as a
preferred dimerization partner, demonstrate that EGFR homo-
dimerization and EGFR/HER2 heterodimerization occur at com-
parable affinities but HER2 has to be expressed at a certain
threshold level to engage into productive EGFR/HER2 complexes
(Hendriks et al, 2003). Given that HER2 protein is expressed at
lower levels than EGFR in the human skin, it is possible that it is
unable to achieve the minimal threshold to function as a
coreceptor.
Our results suggest that the HER receptor dimer distribution
may be different in the skin compared to a solid tumour within the
same patient. It would be interesting to explore the levels of HER-
receptor dimers within the skin and solid tumours of patients
receiving HER-kinase directed therapies to address the question of
HER-receptor dimer discordance. We could not directly demon-
strate this discrepancy due to the lack of availability of tissue from
paired skin and tumour biopsies. However, the skin samples
analyzed in this study were obtained from patients with breast
cancer. All 16 skin specimens only demonstrated the presence of
EGFR homodimers and it is unlikely that the HER receptor dimer
distribution would be identical in all 16 tumours. Interestingly, a
recent study (Tan et al, 2004) described skin rash in 61% of 15
patients with metastatic breast cancer treated with erlotinib even
though 14 of the 15 tumours were EGFR negative and had no
objective clinical responses. This analysis of paired skin and
tumour tissue clearly supports our results and questions the utility
of skin rash as an optimal surrogate outcome marker for EGFR-
directed therapies. However, skin may still be an effective
pharmacodynamic surrogate for EGFR targeted drug activity.
Other studies correlated the occurrence and the grade of the skin
rash after HER-kinase therapies with clinical outcome, but again
this concordance was not present in all studies (Baselga, 2003;
Clark et al, 2003; Cohen et al, 2003; Saltz et al, 2003; van Zandwijk,
2003). Here, we provide a potential molecular explanation for this
discrepancy. Severity of skin rash most likely relates to the number
of EGFR homodimers in the skin and may not always represent the
HER-kinase signaling status in a coexisting tumour.
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